Periostin (PN), an extracellular matrix protein, is reported to be overexpressed in a variety of human cancers and its functions appear to be linked to tumor metastasis. Our previous results show that engineered PN overexpression promotes ovarian tumor growth and dissemination in vivo. In the present study, we developed a neutralizing monoclonal antibody (mAb) to PN, named MZ-1, and investigated its effects on human ovarian tumor growth and metastasis. Our in vivo studies showed significant growth inhibition by MZ-1 on both subcutaneous (sc) and intraperitoneal (ip) tumors derived from the PNexpressing ovarian cancer cell line A2780. In addition, MZ-1 treatment led to a reduction of the metastatic potential of these A2780 ip tumors. The in vivo antitumor effects of MZ-1 were linked to its specific inhibition of anchorage-independent growth and survival of PN-expressing cells, as well as its neutralizing effects on PN-induced cancer cell migration and invasion. The data suggests that blocking PN expression may be a novel approach for treating the subset of invasive ovarian tumors that overexpress PN protein.
Introduction
Ovarian cancer is one of most lethal cancers in women and causes around 14,000 death annually in the U.S. (1) . One major challenge of ovarian cancer treatment is the lack of reliable early diagnostic methods for this asymptomatic disease. As the result, a majority of patients are diagnosed with advanced disease characterized by widespread tumor metastasis in the peritoneal cavity (2) . Despite high initial response rates to aggressive primary chemotherapy, this group of patients frequently develop drug resistance resulting in poor prognosis and the 5-year survival rate has not risen above 20-25% (3). Clearly, there exists a need for more effective therapeutic strategies for ovarian cancer treatment.
Biologically targeted therapy has become a main stream strategy for cancer treatment in the past two decades, due to an improved understanding of the genetic alterations underlying tumor progression (4, 5) . Development of new treatments with trastuzumab (Herceptin) and bevacizumab (Avastin), two mAbs that selectively target Her2-neu and VEGF gene products have shown significant antitumor efficacy in clinical trials (6, 7) .
Compared to traditional treatment options that come with a price of toxicity to normal tissues, targeted therapy is more specific and less toxic thus more effective. In this regard, design of novel therapeutic agents against molecular targets that are essential for ovarian cancer metastasis represents an important step toward discovering more effective and rational therapy for this deadly disease.
Periostin (PN) has attracted increasing attention because it is frequently overexpressed in a variety of epithelial carcinomas including ovarian cancer and its function is implicated 4 in tumor metastatic growth. Analyses of clinical samples have revealed a correlation between PN overexpression and liver metastasis of colon cancer (8) , distant metastasis of melanomas (9) , lymph node metastasis of oral cancer (10) , head and neck cancer (11) , and cholangiocarcinoma(12). Moreover, PN overexpression or elevated PN serum levels have been demonstrated to be associated with other clinical parameters such as later stages, higher grade, and worse survival outcomes (13) (14) (15) (16) (17) (18) (19) (20) . Furthermore, the prometastatic role of PN also has been confirmed in experimental animal models derived from engineered PN-expressing cancer cells (8, 11, 21) . Evidence indicates the modulation of this molecule in Epithelial-Mesenchymal Transition (EMT) that is a critical initiation step of the tumor metastasis cascade (22) . As an adhesion molecule and chemoattractant, purified PN protein promotes cancer cell adhesion, migration and invasion with all 3 functions important for tumor metastasis (21, 23, 24) . Exogeneous PN expression also results in increased cell invasive capabilities (11, 25) ; while silencing the PN gene by small interfering RNA suppresses cell migration and invasion phenotypes (25) . It also has been reported that PN can promote cancer cell survival through activation of the PI3-k/Akt signaling pathway (8, 21, 23) .
Our previous studies have shown that PN is frequently overexpressed in primary ovarian tumors (21, 24) and exogeneous expression of PN in ovarian cancer cells promotes tumor growth and metastasis in experimental animal models (21) . These data suggest PN may be a promising target for anti-metastatic therapy of ovarian cancer. To test this more directly, we produced a specific anti-PN mAb, named MZ-1, that blocks the biological functions of PN, and now report its effect on human ovarian tumors grown in In vitro migration/invasion assay. Cell migration and invasion assays were performed as previously described (21) . For migration, one hundred thousand tumor cells in 100 μL SFM were added to the culture plate inner chamber and allowed to migrate overnight in a 37 o C incubator. PN (or BSA, 1μg/mL), or MZ-1 (or control antibody, 20μg/mL) was added to an outerchamber. Cell migration results were quantitated in terms of the average number of cells/microscopic field at a 20-fold magnification. In all cases, at least 6 separate fields were counted per membrane, and all experiments were carried out in triplicate two times. For invasion, cells were seeded into inner chambers in which membranes were pre-coated with growth factor reduced (GFR) Matrigel (BD Biosciences, San Jose, CA) and the cells reaching the bottom chambers were quantitated by direct visual cell count after 24 hr, as described previously (26) . 
Results

Characterization of anti-PN mAb MZ-1.
A panel of candidate anti-PN mAbs (13) was produced by hybridomas derived from mice immunized with His-tagged PN protein, (40μg/mL) led to a mild (5-10%), but not statistically significant reduction of proliferation over a period of six days (Fig. 3a) . The inhibition was independent of serum concentrations. Similar results were obtained when growing A2780 cells on ultra-low attachment plates (Fig. 3b) . We then examined the influence of mAb MZ-1 on A2780 cell proliferation in soft agar. As shown in Fig. 3c (left column), treatment with MZ-1 (100μg/ml in the middle layer) significantly suppressed the colony formation when compared to medium control (52% reduction, p<0.001) and antibody control (44% reduction, p<0.001). MZ-1 also showed significant inhibitory effects (36% reduction, p<0.001 vs. control antibody) on another PN-expressing cell, TOV-112D. However, MZ-1 did not show any effects on ES2 and SKOV-3 (Fig. 3c) , two cell lines with low or non-PN-expression levels. Another PN-negative cell line OAW-42 did not grow in soft agar in our experiments.
MZ-1 induces apoptosis of ovarian cancer cells in vitro.
We employed two approaches to determine the effects of mAb MZ-1 on ovarian tumor cell survival. First, cells were grown on plastic surfaces and exposed to MZ-1 (40μg/mL) for four days in SFM. Tumor cell apoptosis, including both early and late apoptosis, was evaluated by the Annex V/ PI (propidium iodide) system. As shown in Fig. 4a , compared to antibody control, four days of MZ-1 treatment increased A2780 cell apoptosis by 69% (p=0.01).
The effect of MZ-1 on TOV-112D cells was much weaker than that on A2780 cells and 
no effect was seen on the other three ovarian tumor cell lines. Second, cells were grown on ultra-low-attachment plates and exposed to MZ-1 in the absence of serum for four days. Tumor cells anoikis, a form of apoptosis that is caused by cell detachment from the ECM (28), was assessed by trypan blue exclusion method. In contrast to control antibody, MZ-1 treatment efficiently induced the anoikis of A2780 cells by 2.3 fold (p=0.04). Similar to the apoptosis seen on plastic surfaces, treatment with MZ-1 had a weaker effect on TOV-112 cells and none on other cell lines (Fig. 4b) . It has been reported that PN promotes cell survival through activation of Akt/PKB signaling pathway in colon (8) , pancreatic(23) and non-small lung cancer cells (29) . We thus examined Fig.4c) .
MZ-1 inhibits PN-mediated ovarian cancer cell migration and invasion in vitro.
We investigated effects of PN and anti-PN mAb MZ-1 on the metastatic potential of A2780 and TOV-112D cells by in vitro migration and Matrigel invasion assays. As shown in Fig. 4a , PN efficiently elicited a substantial increase in migration of A2780 (2.6 fold) and TOV-112D cells (1.6 fold) when compared to a negative control using BSA. greater than for BSA. In contrast to control antibody that showed no effect, MZ-1 significantly suppressed PN-induced invasion of A2780 cells (≈ 44% reduction) and TOV-112D cells (≈ 47% reduction) (Fig. 5b) . 
possibility, PN expression in culture medium of our TOV-112D cells was not detected by our western blot (data not shown), but was detected by a more sensitive PN ELISA.
Our findings that treatment with PN mAb MZ-1 triggers both ovarian cancer cell apoptosis and anoikis are consistent with previous results from our and other groups. 
